BioMidwest

Found 69,311 articles

• Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies

  1/19/2021

  Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage oncology company developing multi-specific antibodies, today announced a research collaboration and exclusive license agreement that will leverage Merus' proprietary Biclonics® platform

• Inspire Medical Systems, Inc. Announces Appointment of Bryan Phillips as General Counsel

  1/19/2021

  Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea (“OSA”), announced today the appointment of Bryan Phillips as Senior Vice President,

• Alice Pomponio Named Managing Director of American Cancer Society's BrightEdge

  1/19/2021

  The American Cancer Society announced that life sciences industry leader Alice Pomponio has been named managing director of BrightEdge, the ACS philanthropic impact fund that invests in companies to accelerate the Society's mission to fight cancer.

• HealthMyne Appoints National Oncology Leader to Board of Directors

  1/19/2021

  Veteran physician executive Mimi Huizinga brings a deep understanding of the role novel data plays in treatment development and delivery

• Comprehensive Sun Nuclear Solutions for Radiation Therapy QA Adopted by Japan's Ogaki Municipal Hospital

  1/19/2021

  Sun Nuclear Corporation announced that Ogaki Municipal Hospital has selected a collection of Sun Nuclear solutions for its end-to-end Radiation Therapy Quality Assurance program.

• Aptinyx Announces Publication of Review Article Highlighting Preclinical Data in Medicine in Drug Discovery Demonstrating the Potential of NYX-2925 to Treat Chronic, Centralized Pain Conditions

  1/19/2021

  Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the publication of a recent review article in Medicine in Drug Discovery featuring data on its novel NMDA receptor modulator, NYX-2925.

• Health Canada Approves TheraLight Photobiomodulation Systems

  1/19/2021

  TheraLight, LLC, an international photomedicine company and leader in light therapy and photobiomodulation, announced that Health Canada has approved the TheraLight 360 full body photobiomodulation system for use in Canada.

• Zimmer Biomet Appoints Ellison M. Humphrey as Chief Transformation Officer

  1/19/2021

  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that Ellison (Ellie) M. Humphrey has been appointed to the newly created position of Chief Transformation Officer and will report directly to Bryan C. Hanson, President and Chief Executive Officer.

• Neovasc Reducer Featured in Three Peer Reviewed Publications Supporting Reducer Therapy

  1/19/2021

  Neovasc Inc. (“Neovasc” or the “Company”) (Nasdaq, TSX: NVCN) announced today the Neovasc Reducer™ (“Reducer”) was prominently featured in three peer reviewed European Journals.  

• Adam Perer Joins Blue Spark Technologies’ TempTraq Advisory Board

  1/19/2021

  Expands Blue Spark’s research capabilities into predictive machine learning and AI algorithms for predictive disease states

• ONL Therapeutics Names Connie Chang as Chief Operating OfficerCompany expands leadership team as it advances lead candidate ONL1204 beyond retinal detachment into the chronic conditions of glaucoma and dry age-related macular degeneration

  1/19/2021

  ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today announced the appointment of Connie Chang to the newly created position of chief operating officer (COO).

• Orsini Specialty Pharmacy Selected By Glaukos® Corporation As A Specialty Pharmacy Distribution Partner For Photrexa® And Photrexa® Viscous

  1/19/2021

  Orsini Specialty Pharmacy, a leader in rare diseases and gene therapies, announced that it has been selected by Glaukos® Corporation as a specialty pharmacy distribution partner for Photrexa® and Photrexa® Viscous for the treatment of patients with progressive keratoconus and corneal ectasia following refractive surgery See Full Prescribing Information.

• Medibio Granted CE Mark Approval for MEBsleep

  1/19/2021

  Medibio Limited, is pleased to announce that it has received CE Mark approval for its sleep staging software, MEBsleep.

• Esaote North America introduces the MyLab™X8 Ultrasound System into Canada: A fully featured, premium imaging system to meet the most demanding clinical needs in the hospital or in the medical office

  1/19/2021

  Esaote North America announces that the MyLab™X8 Ultrasound System has now been approved in Canada.

• MJ Biotech Wholly Owned Subsidiary, New England Biotech And Joint Venture Partner Genesis Botanical Research Secures CBD Extraction Facility Location

  1/19/2021

  MJ Biotech, Inc., is pleased to announce that it's partner Genesis Botanical Research, has secured the location for the first of their CBD extraction facilities.

• PetMed Express d/b/a 1-800-PetMeds Announces Its Third Fiscal Quarter Financial Results and Its Quarterly Dividend of $0.28 Per Share

  1/19/2021

  PetMed Express, Inc. announced its financial results for the quarter ended December 31, 2020.

• Cardialen Awarded $2.8 Million Federal Grant to Advance Therapy Designed to Treat Dangerous Heart Rhythms

  1/19/2021

  National Institutes of Health grant will support Cardialen’s development of its implantable, low-energy therapy designed to treat atrial fibrillation, a cardiac arrhythmia associated with debilitating shortness of breath, fatigue, pain, and an increased risk of stroke.

• Blink Science, Inc. Names Eric Doherty President

  1/19/2021

  Healthcare Industry Veteran to Lead Blink Science Efforts in Developing the World's First Instant COVID POC Diagnostic Testing Device and Launching a Comprehensive Electronic Medical Passport

• Hillrom Announces Planned Acquisition Of Bardy Diagnostics, Inc.

  1/19/2021

  Hillrom (NYSE: HRC) today announced it has reached a definitive agreement to acquire Bardy Diagnostics, Inc. (BardyDx), an innovator in digital health and a leading provider of ambulatory cardiac monitoring technologies.

• Viewpoint Molecular Targeting(TM) Awarded $5 Million in Phase II SBIR Grants from the National Institutes of Health - National Cancer Institute

  1/19/2021

  - $2 million Phase II SBIR grant awarded to advance image-guided alpha-particle therapy for metastatic melanoma and radioisotope production technologies - Second year of a $2 million Phase II SBIR funding to begin a Phase 1 clinical imaging trial of complementary Pb-203 and Ga-68 diagnostics for metastatic melanoma - $2 million Phase II Small Business Innovation Research (SBIR) grant awarded to fund development activities and advance preclinical studies of VMT-